United States Government Publishing Office publisher pbl distributor dst United States National Archives and Records Administration Office of the Federal Register author aut Government Organization text government publication eng FR Regulatory Information 2014_register executive 2014-03-29 article Notices D09002ee1c7fa41a6 D09002ee1c7fa4255 United States Department of Health and Human Services originator org United States Government Agency or Subagency United States National Institutes of Health originator org United States Government Agency or Subagency This is notice, in accordance with 35 U.S.C. 209 and 37 CFR part 404, that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive start-up option license to practice the inventions embodied in U.S. Patent Application 61/706,396 entitled "Mesothelin Antibodies and Methods for Eliciting Potent Antitumor Activity" [HHS Ref. E-236-2012/0-US-01], PCT Application PCT/US2013/059883 entitled "Mesothelin Antibodies and Methods for Eliciting Potent Antitumor Activity" [HHS Ref. E-236-2012/ 0-PCT-02], and all related continuing and foreign patents/patent applications for the technology family, to H2Bio, Inc. The patent rights in these inventions have been assigned to and/or exclusively licensed to the Government of the United States of America. The prospective exclusive start-up option licensed territory may be worldwide, and the field of use may be limited to: 79 FR 18039 https://www.govinfo.gov/app/details/FR-2014-03-31/2014-07022 2014-07022 fr31mr14-96 4140-01-P https://www.govinfo.gov/app/details/FR-2014-03-31/2014-07022 https://www.govinfo.gov/content/pkg/FR-2014-03-31/html/2014-07022.htm https://www.govinfo.gov/content/pkg/FR-2014-03-31/pdf/2014-07022.pdf 1 p. 18039 18039 79 FR 18039 Prospective Grant of Exclusive License: The Development of a Single Domain Human Anti-Mesothelin Monoclonal Antibody for the Treatment of Human Cancers; Federal Register Vol. 79, Issue NOTICE 2014-07022 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health 2014-04-15 4140-01-P 2014-07022 Notice.

This is notice, in accordance with 35 U.S.C. 209 and 37 CFR part 404, that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive start-up option license to practice the inventions embodied in U.S. Patent Application 61/706,396 entitled "Mesothelin Antibodies and Methods for Eliciting Potent Antitumor Activity" [HHS Ref. E-236-2012/0-US-01], PCT Application PCT/US2013/059883 entitled "Mesothelin Antibodies and Methods for Eliciting Potent Antitumor Activity" [HHS Ref. E-236-2012/ 0-PCT-02], and all related continuing and foreign patents/patent applications for the technology family, to H2Bio, Inc. The patent rights in these inventions have been assigned to and/or exclusively licensed to the Government of the United States of America. The prospective exclusive start-up option licensed territory may be worldwide, and the field of use may be limited to:

Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before April 15, 2014 will be considered. Exclusive Licenses: Development of Single Domain Human Anti-Mesothelin Monoclonal Antibody for Treatment of Human Cancers , lambertsond@mail.nih.gov Vol. 79, no. 61 Office of the Federal Register, National Archives and Records Administration 2014-03-31 continuing daily deposited born digital 315 p. Table of Contents: AE 2.7: GS 4.107: AE 2.106: KF70.A2 https://www.govinfo.gov/app/details/FR-2014-03-31 P0b002ee1881b825e 0097-6326 0042-1219 0364-1406 769-004-00000-9 000582072 f:fr31mr14 https://www.govinfo.gov/app/details/FR-2014-03-31 https://www.govinfo.gov/content/pkg/FR-2014-03-31/pdf/FR-2014-03-31.pdf https://www.govinfo.gov/content/pkg/FR-2014-03-31/xml/FR-2014-03-31.xml fdlp 17849 18151 DGPO 2014-03-29 2024-06-02 FR-2014-03-31 machine generated eng FR FR-2014-03-31 79 61